Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05085496 · ClinicalTrials.gov registry record · Phase 1
Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC
A Phase 1 study of Locally Advanced Skin Squamous Cell Carcinoma and Resectable Skin Squamous Cell Carcinoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05085496 is a Phase 1 study of Locally Advanced Skin Squamous Cell Carcinoma and Resectable Skin Squamous Cell Carcinoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05085496, a Phase 1 study of Locally Advanced Skin Squamous Cell Carcinoma and Resectable Skin Squamous Cell Carcinoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial tests the safety and side effects radiotherapy in combination with atezolizumab in treating patients with cutaneous squamous cell cancer that has spread to nearby tissue or lymph nodes (locally advanced) and can be removed from surgery (resectable) or cannot be remove by surgery (unresectable). Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving radiotherapy in combination with atezolizumab may help improve outcomes for remission (cancer that is under control) than taking either treatment separately.
Conditions Studied
Interventions
- BIOLOGICAL Atezolizumab
- RADIATION Stereotactic Body Radiation Therapy
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-04-19 |
| Est. Completion | 2027-09-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05085496
The ClinicalTrials.gov registry entry for NCT05085496 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Locally Advanced Skin Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Atezolizumab is the first listed.
NCT05085496 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05085496 about?
NCT05085496 is a clinical study titled "Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC". This phase I trial tests the safety and side effects radiotherapy in combination with atezolizumab in treating patients with cutaneous squamous cell cancer that has spread to nearby tissue or lymph nodes (locally advanced) and can be removed from surgery (resectable) or cannot be remove by surgery (...
What is the current status of trial NCT05085496?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-04-19. Estimated completion is 2027-09-10.
What conditions does trial NCT05085496 study?
This clinical trial studies the following conditions: Locally Advanced Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma.
What interventions are being tested in trial NCT05085496?
The interventions under investigation include: Atezolizumab (BIOLOGICAL), Stereotactic Body Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT05085496?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05085496 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Skin Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Locally Advanced Skin Squamous Cell Carcinoma
All registered trials for this condition
Resectable Skin Squamous Cell Carcinoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.